Can Intramuscular Pentobarbital Cause Burning at the Injection Site?
Yes, intramuscular pentobarbital injection can cause tissue irritation at the injection site, though the FDA labeling specifically warns about tissue irritation rather than explicitly describing a "burning" sensation. 1
Key Evidence from FDA Labeling
The FDA drug label for pentobarbital explicitly states that IM injection of sodium salts of barbiturates should be made deeply into a large muscle, with no more than 5 mL at any one site "because of possible tissue irritation." 1 This tissue irritation can manifest as discomfort, pain, or burning sensations at the injection site.
Important Administration Guidelines
The FDA labeling provides specific precautions to minimize injection site reactions 1:
- Inject deeply into large muscle mass (not superficial)
- Limit volume to ≤5 mL per injection site to reduce tissue irritation
- The solution is NOT suitable for subcutaneous administration (explicitly contraindicated) 1
- Monitor vital signs after IM injection of hypnotic doses
Clinical Context and Mechanism
While the available guidelines 2, 3 focus primarily on efficacy and safety monitoring for pentobarbital sedation rather than injection site reactions, the mechanism of tissue irritation is related to:
- High alkalinity of pentobarbital sodium solution (pH 11) 1
- The sodium salt formulation itself
- Local tissue response to barbiturate deposition
Research on injection pain mechanisms 4 demonstrates that various factors including medication pH, osmolality, and injection technique influence pain perception, though specific studies on pentobarbital injection site reactions are limited in the provided evidence.
Common Pitfalls to Avoid
- Subcutaneous injection: Absolutely contraindicated and would likely cause significant burning and tissue damage 1
- Superficial IM injection: Increases risk of irritation
- Exceeding 5 mL volume: Concentrates irritant effect in smaller tissue area
- Rapid injection: May intensify local discomfort
The tissue irritation warning in the FDA label should be taken as confirmation that local discomfort, including potential burning sensations, is an expected adverse effect of IM pentobarbital administration when proper technique is not followed or even with proper technique in some patients.